Simcere Pharmaceutical Group Limited (Simcere Pharma) expects a solid top- and bottom-line expansion for the six months ended 30 June 2026 (1H 2026), according to a profit alert filed with the Hong Kong Stock Exchange on 30 July 2026.

Revenue Outlook • Management projects revenue of RMB 4.55 billion–4.61 billion, an increase of roughly 26.9 %–28.6 % versus the restated RMB 3.59 billion recorded in the prior-year period (1H 2025). • Growth is attributed mainly to stronger sales from the company’s innovative pharmaceutical portfolio and higher income from out-licensing activities.

Profitability Guidance • Profit attributable to equity shareholders is estimated at RMB 810 million–860 million, representing year-on-year growth of about 34.8 %–43.1 %. • On an adjusted basis—excluding fair-value movements, redemption-liability interest and associated tax effects—profit is expected to reach RMB 0.95 billion–1.00 billion, up approximately 46.5 %–54.2 % from the restated RMB 0.65 billion a year earlier.

Accounting Note The 1H 2025 comparative figures have been restated to reflect the October 2025 acquisition of Xianwei (Hainan) Biotechnology Co., Ltd., accounted for as a business combination under common control.

Next Steps Simcere Pharma is finalising its unaudited interim results, scheduled for release in late August 2026. The figures in the profit alert are based on preliminary management accounts and remain subject to review by auditors and the board’s audit committee.

Shareholders and prospective investors are urged to exercise caution when dealing in the company’s shares until the official interim results are published.